IndraLab

Statements

P5091 activates lenalidomide. 1 / 1

| 1

reach

"To determine whether P5091 similarly affects purified patient MM cells, tumor cells from 8 MM patients, including those relapsing after multiple prior therapies such as bortezomib, lenalidomide, and Dex, were treated with P5091."

22975377

INDRA sources:

Colored badges next to statement headings correspond to evidence counts from knowledge sources, as shown below. Badges to the left of the | separator correspond to curated knowledge base sources, and badges to the right of it correspond to machine reading systems.

IndraLab

Statements

P5091 activates lenalidomide. 1 / 1

INDRA sources:

Databases

Reading